As of 2026-09-09, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -7.24 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.10 GBP, the upside of ImmuPharma PLC is -276.58%.
Based on its market price of 4.10 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 276.58%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.24 - -7.24 | -7.24 | -276.58% |
| P/E | (5.97) - (6.28) | (6.04) | -247.4% |
| DDM - Stable | (3.07) - (7.47) | (5.27) | -228.5% |
| DDM - Multi | (1.62) - (3.16) | (2.15) | -152.4% |
| Market Cap (mil) | 26.97 |
| Beta | 1.11 |
| Outstanding shares (mil) | 6.58 |
| Enterprise Value (mil) | 26.57 |
| Market risk premium | 5.98% |
| Cost of Equity | 14.42% |
| Cost of Debt | 5.00% |
| WACC | 9.43% |